NYSE:RRMS (RRMS) (RRMS) Stock Price, News & Analysis → Top Stock Unveiled! (From Darwin) (Ad) Free RRMS Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Share Share Today's Range$27.16▼$27.1650-Day Range N/A52-Week Range$6.67▼$32.44VolumeN/AAverage Volume205,322 shsMarket CapitalizationN/AP/E Ratio63.16Dividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get (RRMS) alerts: Email Address Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! About (RRMS) Stock (NYSE:RRMS)Rose Rock Midstream, L.P. owns, operates, develops and acquires diversified portfolio of midstream energy assets. The Company is engaged in providing midstream energy related services, such as crude oil gathering, transportation, storage, distribution and marketing in Colorado, Kansas, Minnesota, Montana, North Dakota, Ohio, Oklahoma, Pennsylvania, Texas and Wyoming. Its segments include Transportation, Facilities, and Supply and Logistics. Its Transportation segment operates crude oil pipelines and truck transportation businesses in the United States. Its Facilities segment operates crude oil storage and terminal businesses in the United States. Its Supply and Logistics segment operates a crude oil marketing and blending business in the United States. The Company operates in the Bakken Shale in North Dakota and Montana, the Denver-Julesburg Basin (DJ Basin) and the Niobrara Shale in the Rocky Mountain region, and the Granite Wash and Mississippi Lime Play in the Mid-Continent region.Read More Ad WealthPressNew trading system called MSFT, NVDA & MSFTLook 2023 kind of sucked from a trading standpoint… Despite the market finishing 24% higher…. Just seven stocks did all of the work… Unless you were holding or actively trading those 7 stocks, your trading year probably wasn’t as fruitful as you had hoped… According to my research, my new trading system would have spotted all seven of the “Magnificent stocks” MONTHS before they reached the highs they are trading at today.Just follow this link here! RRMS Stock News HeadlinesMay 14, 2024 | msn.comTreatment hopes dashed for MS sufferersMay 8, 2024 | msn.comMorgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ StocksMay 1, 2024 | finance.yahoo.comImmunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journalApril 26, 2024 | finance.yahoo.comMultiple Sclerosis Market To Reach USD 39.9 Billion By 2032, Report By DataHorizzon ResearchApril 10, 2024 | finance.yahoo.comGranite Telecommunications Boosts EPIK Solution with Strategic Rapid Response Monitoring AllianceApril 4, 2024 | markets.businessinsider.comPolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximabMarch 27, 2024 | msn.comHow Everclear’s Art Alexakis combines rock and comedy to fight MSMarch 26, 2024 | msn.comWhen Does SPMS Begin?March 22, 2024 | msn.comSetPoint joins FDA’s TAP programme with MS deviceMarch 15, 2024 | msn.comUnveiling Atlanta's Culinary Gems with Mike Jordan and Max HinesMarch 14, 2024 | msn.comSetPoint wins second FDA breakthrough device nod for neurostim deviceMarch 13, 2024 | sg.finance.yahoo.comExplainer-What is bitcoin's 'halving', and does it matter?March 13, 2024 | finance.yahoo.comSetPoint Medical Receives FDA Breakthrough Device Designation for its Neuroimmune Modulation Platform for the Treatment of Multiple SclerosisMarch 11, 2024 | finanznachrichten.dePolTREG S.A.: PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in PolandMarch 11, 2024 | markets.businessinsider.comPolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in PolandFebruary 29, 2024 | finance.yahoo.comEMD Serono Presents New MAVENCLAD® Data Supporting Cognitive Function BenefitsFebruary 28, 2024 | msn.comIndia gets breakthrough multiple sclerosis drug, but could be unaffordable to many at Rs 10+ lakh a yrFebruary 27, 2024 | msn.comMultiple sclerosis: SPMS vs. RRMS explainedFebruary 27, 2024 | finance.yahoo.comOM1 to Present Research on Multiple Sclerosis at ACTRIMS Forum 2024February 23, 2024 | msn.comChampioning Justice: Unveiling the Impact of Gideon's Promise at "Igniting Change" EventFebruary 21, 2024 | tmcnet.comPolTREG appoints Dan Shelly as Chief Business Development OfficerFebruary 12, 2024 | msn.comKadarius Toney trade regrade: Who won between Chiefs, Giants after WR's Super Bowl scratchFebruary 1, 2024 | msn.comBlack and Hispanic Women With Multiple Sclerosis Are More Likely to Have Complicated PregnanciesJanuary 31, 2024 | finanznachrichten.deSandoz Group: Sandoz launches first and only biosimilar for multiple sclerosis, Tyruko® (natalizumab), in GermanyJanuary 31, 2024 | msn.comSandoz launches biosimilar for multiple sclerosis in GermanySee More Headlines Receive RRMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for (RRMS) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE SectorN/A Industry N/A Sub-IndustryN/A Current SymbolNYSE:RRMS CUSIPN/A CIK1527622 Webwww.semgroupcorp.com Phone+1-918-5248100FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E Ratio63.16 Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report RRMS Stock Analysis - Frequently Asked Questions Is (RRMS) a good dividend stock? (RRMS) (NYSE:RRMS) pays an annual dividend of $2.64 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 613.95%. Payout ratios above 75% are not desirable because they may not be sustainable. Read our dividend analysis for RRMS. What other stocks do shareholders of (RRMS) own? Based on aggregate information from My MarketBeat watchlists, some companies that other (RRMS) investors own include Aegean Marine Petroleum Network (ANW), Chipotle Mexican Grill (CMG), Endologix (ELGX), Express (EXPR), Hudson Technologies (HDSN), Pentair (PNR), Charles Schwab (SCHW), USG (USG), CARBO Ceramics (CRR) and Ritter Pharmaceuticals (RTTR). This page (NYSE:RRMS) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages...Weiss Ratings | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding (RRMS) Please log in to your account or sign up in order to add this asset to your watchlist. Share (RRMS) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.